AST 005

Drug Profile

AST 005

Alternative Names: AST-005

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Exicure
  • Class Anti-inflammatories; Antipsoriatics; Immunotherapies; Nucleic acids; Skin disorder therapies; Small molecules
  • Mechanism of Action Tumour necrosis factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Psoriasis

Highest Development Phases

  • Phase I Psoriasis

Most Recent Events

  • 12 Dec 2016 Exicure and Purdue Pharma agree to co-develop AST 005 for Plaque psoriasis
  • 12 Dec 2016 Exicure has patents pending for AST 005
  • 12 Dec 2016 Exicure completes a phase I trial in Plaque psoriasis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top